Immunogenicity and safety of defective vaccinia virus Lister: Comparison with modified vaccinia virus Ankara

Journal of Virology

Volumn 76, Issue 15, 2002, Pages 7713-7723

  Ober, B T ^a   Bruhl P ^a   Schmidt, M ^a   Wieser, V ^a   Gritschenberger, W ^a   Coulibaly, S ^a   Savidis Dacho, H ^a   Gerencer, M ^a   Falkner, F G ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CHICKEN; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; VACCINATION; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; DEFECTIVE VIRUSES; GENETIC VECTORS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, SCID; RABBITS; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0036310570     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.15.7713-7723.2002     Document Type: Article

References (46)

1. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
2. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses
3. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line
4. Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques
5. Poxvirus recombinants as live vaccines
6. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo
7. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells
8. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors
9. Transient dominant selection of recombinant vaccinia viruses
10. Smallpox as a biological weapon: Medical and public health management
11. Smallpox and vaccinia
12. Molecular analysis of the association of HLA-B53 and resistance to severe malaria
13. p53 mutations in human cancers
14. Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line
15. Dominant host range selection of vaccinia recombinants by rescue of an essential gene
16. Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression
17. Small pox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78)
18. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
19. The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism
20. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Standard percutaneous revaccination of children who receive primary percutaneous vaccination
21. Characterization of an in situ IFN-gamma ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization
22. Strategies for immunotherapy of cancer
23. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
24. Analysis of p53 expression in human turnouts: An antibody raised against human p53 expressed in Escherichia coli
25. Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection
26. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
27. p53: A potential target antigen for immunotherapy of cancer
28. Safe and effective poxvirus vectors-NYVAC and ALVAC
29. Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: Characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens
30. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine
31. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
32. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
33. Transient marker stabilisation: A general procedure to construct marker-free recombinant vaccinia virus
34. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
35. Heat shock response to vaccinia virus infection
36. MVA-Stufenimpfung gegen pocken
37. Nonreplicating vaccinia vector efficiently expresses recombinant genes
38. NYVAC: A highly attenuated strain of vaccinia virus
39. Fowlpox virus as a vector in non-avian species
40. Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis
41. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model
42. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model
43. T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS